Medindia

X

Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability

Tuesday, April 15, 2008 General News J E 4
Advertisement
BOSTON, April 14 Perceptive Informatics, thetechnology subsidiary of PAREXEL International Corporation (Nasdaq: PRXL),today announced the availability of its clinical site management andmonitoring software, IMPACT(R) MySites, on a portable USB drive. Clinicalmonitors can now securely upload site visit information onto the USB drive,without carrying their laptop computers with them. The MySites monitoringsolution is a part of the IMPACT suite, Perceptive Informatics' market-leadingClinical Trial Management System (CTMS).

"We expect that clinical monitors will benefit from increased flexibility,productivity, and efficiency with the option to easily and securely capturesite visit information from anywhere in the world at any time, using the newportable functionality of the IMPACT MySites USB drive," said Todd Joron,Corporate Vice President and General Manager of Perceptive Informatics atPAREXEL. "This capability represents an important step toward a truly mobileeClinical environment."

The IMPACT MySites module supports on-line and off-line monitoringactivities and the collection of associated data during site visits byclinical monitors in the field. With the USB drive capability, IMPACT MySitesis a zero-footprint solution, requiring no software installation. As theentire MySites module is housed on the USB drive, information collected byclinical monitors is securely stored and later synchronized with the IMPACTdatabase.

The Perceptive Informatics IMPACT system has more than 26,000 users inover 85 countries -- the largest number of users of any CTMS solution on themarket. Biopharmaceutical companies rely on the IMPACT solution, which enablescomplete trial management and planning, to manage, track, and organizeclinical trial management data. Perceptive's IMPACT software interfaces withInteractive Voice and Web Response Systems (IVRS/IWRS) as well as electronicdata capture (EDC) and data management applications, in addition to financialreporting.

About Perceptive Informatics, a PAREXEL Company

PAREXEL's Technology Division, Perceptive Informatics, combines clinicalknowledge, quality and regulatory experience with advanced technology todecrease time to market, risk and cost associated with clinical trials.Perceptive's portfolio includes Medical Imaging, Clinical Trial ManagementSystems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), andIntegration Services as well as web-based portal solutions, tracking tools,electronic diaries and investigator database solutions. Perceptive offersmedical imaging services to rapidly and objectively assess the safety andefficacy of new drugs, biologics and medical devices in clinical trials. TheIMPACT(R) solution is Perceptive's market-leading CTMS product with 26,000users worldwide, and Perceptive's INITIATOR(TM) trial management producttargets the needs of Phase I units. For more information about PerceptiveInformatics, visit www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceuticalservices organization, providing a broad range of knowledge-based contractresearch, medical communications and consulting services to the worldwidepharmaceutical, biotechnology and medical device industries. Committed toproviding solutions that expedite time-to-market and peak-market penetration,PAREXEL has developed significant expertise across the development andcommercialization continuum, from drug development and regulatory consultingto clinical pharmacology, clinical trials management, medical education andreimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, providesadvanced technology solutions, including medical imaging, to facilitate theclinical development process. Headquartered near Boston, Massachusetts,PAREXEL operates in 64 locations throughout 51 countries around the world, andhas more than 7,300 em
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Adaptis Promotes Roya Rezai to Chief Compliance Of...
S
Kosan Initiates Phase 2 Trial of Epothilone KOS-15...